Sergio Fazio, MD, PhD

Professor of Medicine, Director of Preventive Cardiology, Oregon Health & Science University, Portland, OR

A graduate of the medical school of the University of Rome, Italy, Dr. Fazio continued at the same institution with a fellowship in Metabolic Diseases. In 1985, he undertook a Ph.D. program in Experimental Medicine at the University of Siena, Italy, and completed it at the University of California, San Francisco (UCSF}. In 1988, Dr. Fazio joined the Gladstone Institute of Cardiovascular Disease, UCSF, as a postdoctoral scientist first, and then as a Staff Scientist (Instructor in Medicine, UCSF}. In 1993, Dr. Fazio joined the faculty of the School of Medicine at Vanderbilt University as an Assistant Professor In the Division of Endocrinology and Diabetes. There, he co-founded the Vanderbilt Lipid Clinic and became Director of the Vanderbilt Lipid Laboratory. He was promoted to the rank of Associate Professor in July 1998. In November of 1999, Dr. Fazio joined the Division of Cardiovascular Medicine to become the co­Director of the Atherosclerosis Research Unit. He was promoted to Professor in November 2002. In 2011, he was appointed the Cornelius Vanderbilt Chair of Cardiovascular Medicine and Chief of the section of Cardiovascular Disease Prevention. Since July 2014, he holds the William and Sonja Connor chair of Preventive Cardiology at the KCVI of OHSU. His clinical interest is the management of dyslipidemic patients. He participates in clinical trials to study the effectiveness and efficacy of lipid-lowering drugs, and is involved in the determination of new mutations causing altered lipid levels in humans. Dr. Fazio's NIH-supported research portfolio focuses on the pathogenesis of genetic dysllpidemias, the early cellular events in atherogenesis, and gene therapy approaches to atherosclerosis. He was an Established Investigator of the American Heart Association and has received about 20 NIH grants as either Pl or co-PI. He has published over 240 papers, including original articles, reviews, editorials, and book chapters. He has been a charter member of the Study Section Atherosclerosis and Inflammation in Cardiovascular Disease of the NIH-NHLBI from 2006 to 2010. He is member of the American Society for Clinical Investigation and of the Association of American Physicians. He is on the editorial board of Arteriosclerosis, Thrombosis and Vascular Biology, Journal of Lipid Research, Journal of Clinical Endocrinology and Metabolism, and Circulation Research, and associate editor for the Journal of Clinical Lipldology.

Recent & Upcoming Conference Sessions

Pri-Med® Midwest |Continuing Medical Education (CME) | Rosemont, IL

Midwest Annual Conference

Practical Guide to the Management of Atherogenic Lipids

Wednesday, October 10, 2018

12:45 PM - 2:00 PM Room 26, Level 2

Pri-Med® West |Continuing Medical Education (CME) | Anaheim, CA

West Annual Conference

Practical Guide to the Management of Atherogenic Lipids

Wednesday, May 30, 2018

10:30 AM - 11:45 AM